Nimotuzumab Combined With the Stupp Regimen for Postoperative Residual Glioblastoma

This is a prospective, single-arm study. The study population consists of adult patients with a confirmed diagnosis of EGFR-positive high-grade glioma who have radiographic residual tumor following surgical resection. Participants will receive nimotuzumab in combination with the standard Stupp regimen after glioma surgery.

NCT Number	NCT07707973
Lead Sponsor	Tianjin First Central Hospital
Conditions	Glioma, Malignant
Enrollment	50 participants
Start Date	2026-07-03
Primary Completion	2028-01-03 (estimated)
Study Completion	2029-06-03 (estimated)
Updated on ClinicalTrials.gov	2026-07-16